Top institutional investors include BlackRock Inc. (8.30%), FMR LLC (2.87%), Clearbridge Investments LLC (2.68%), Renaissance Technologies LLC (1.88%), Norges Bank (1.44%) and The Manufacturers Life Insurance Company (1.28%). AC Investment Inc. delivers machine learning based share price forecast. Find out now with a free analysis on Alexion Pharmaceuticals. AstraZeneca stock has the potential to push above $61 per share, aided in part by the drug maker's pending buyout of Alexion, says Jefferies. Find the latest Earnings Report Date for Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com. Historical Ratings. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, and Tanisha Carino. Esq., Exec. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com. View which stocks are hot on social media with MarketBeat's trending stocks report. 23 Wall Street analysts have issued ratings and price targets for Alexion Pharmaceuticals in the last 12 months. AstraZeneca stock has the potential to push above $61 per share, aided in part by the drug maker's pending buyout of Alexion, says Jefferies. Based on an average daily trading volume, of 2,930,000 shares, the days-to-cover ratio is currently 2.7 days. Company Releases for Alexion Pharmaceuticals Inc. Tuesday, March 16, 2021. With Alexion Pharmaceuticals stock trading at $152.75 per share, the total value of Alexion Pharmaceuticals stock (market capitalization) is $33.43B. Last 30 Days. Alexion also produces Strensiq, which treats a rare disorder known as hypophosphatasia. Good spot for Alexion Pharmaceuticals. Shares in Alexion Pharmaceuticals Inc are currently priced at $151.56. Editor of top German newspaper suspended in compliance probe. One share of ALXN stock can currently be purchased for approximately $150.94. Alexion Pharmaceuticals updated its FY 2020 Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Learn more about I Know First. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Get the latest Alexion Pharmaceuticals (ALXN) stock price quote with real-time news, financials, charts and other important investing information. Limited Time Only. 87.27% of the stock of Alexion Pharmaceuticals is held by institutions. Pre-Market earnings guidance on Tuesday, January, 12th. It considers technical and fundamental factors and is a good starting point for evaluating a stock. By May 28th, Americans could be faced with a difficult choice: Accept a "Great Reset" and risk losing the American way of life... or stand up and fight back to save what's left of the American dream. The biopharmaceutical company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.56 by $0.40. View our earnings forecast for Alexion Pharmaceuticals. PEG Ratios below 1 indicate that a company could be undervalued. Looking for new stock ideas? Disclaimer. View Alexion Pharmaceuticals' Short Interest. A "hold" rating indicates that analysts believe investors should keep any existing positions they … Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Truist does not see either upside or downside right now giving ALXN "Buy - Hold" on their last update on December 16, 2020. In the past three months, Alexion Pharmaceuticals insiders have not sold or bought any company stock. As of February 12th, there was short interest totaling 7,900,000 shares, an increase of 80.4% from the January 28th total of 4,380,000 shares. Wall Street analysts have given Alexion Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. CNN Sans™ & © 2016 Cable News Network. What this means: Alexion Pharm Inc (ALXN) gets a very positive evaluation from InvestorsObserver's ranking system. Frankfurt Stock Market & Finance report, prediction for the future: You'll find the Alexion Pharmaceuticals share forecasts, stock quote and buy / sell signals below. Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. This suggests the company knows how to effectively market the drugs it develops, but it still has the Achillion acquisition to incorporate. 09:24 AM ET. Historical Ratings. ALXN stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Magnetar Financial LLC, Janus Henderson Group PLC, The Manufacturers Life Insurance Company, Westchester Capital Management LLC, Alpine Associates Management Inc., Carlson Capital L P, and Water Island Capital LLC. Alexion Pharmaceuticals currently has 16 hold ratings, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock is down by more than 5% after the company revealed that it would acquire Alexion in a $39 billion deal. AZN shares are falling partly because of the company’s decision to spend $39 billion to acquire Alexion, an American company valued at more than $26 billion. Receive a free world-class investing education from MarketBeat. Find the latest Alexion Pharmaceuticals, Inc. (ALXN) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. The company was founded in 1992 and is headquartered in Boston, Massachusetts. Alexion Pharmaceuticals has a P/B Ratio of 2.96. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Alexion Pharmaceuticals had a net margin of 16.32% and a trailing twelve-month return on equity of 23.16%. Approximately 3.6% of the shares of the company are short sold. The business's revenue was up 15.0% compared to the same quarter last year. Institutions hold 93.36% of the Float. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud). Vote “Underperform” if you believe ALXN will underperform the S&P 500 over the long term. The company provided EPS guidance of for the period. The biopharmaceutical company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.51 billion. The P/E ratio of Alexion Pharmaceuticals is 35.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 40.72. Alexion Pharmaceuticals Stock Forecast NASDAQ:ALXN Price Target and Analyst Ratings. You Must Recognize Your Own Achievements First Before Expecting … (Add your “outperform” vote. All rights reserved. View real-time stock prices and stock quotes for a full financial overview. The combination is tenuous, but not impossible. Ludwig Hantson has an approval rating of 75% among Alexion Pharmaceuticals' employees. Company Forecast. Alexion Pharmaceuticals Stock Forecast is based on your current time horizon. Other top laggards in the FTSE are Fresnillo, PolyMetal, and BHP. Stock analysis for Alexion Pharmaceuticals Inc (ALXN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The company's average rating score is 2.35, and is based on 6 buy ratings, 16 hold ratings, and no sell ratings. The price has been going up and down for this period, and there has been a -0.76% loss for the last 2 weeks. VP and Chief Commercial & Global Operations Officer. Scan for strong stocks. On average, they anticipate Alexion Pharmaceuticals' share price to reach $155.68 in the next twelve months. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Jeff Brown, member of a D.C.-based advocacy group, explains what every American must do before May 28th to preserve his assets and thrive. Was AstraZeneca Smart to Sell Its Moderna Shares? Most stock quote data provided by BATS. ), Alexion Pharmaceuticals has received 770 “underperform” votes. The stock was up 2.39% to $118.00 in premarket trading. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last twelve months. Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology, AstraZeneca Sold Its Stake in Rival Covid-19 Vaccine Maker Moderna for More Than $1 Billion, AstraZeneca sold its stake in Moderna for more than $1 billion last year. All rights reserved. Alexion Pharmaceuticals, Inc. Common Stock (ALXN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 09:11 PM ET Overall Alexion Pharmaceuticals is expecting the drug to become an increasing and more important part of the company’s portfolio. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Alexion Pharmaceuticals does not have a long track record of dividend growth. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. There are currently 16 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. © 2020 Cable News Network. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Of note is the ratio of Alexion Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 15.43% of US stocks have a lower such ratio. Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? Since then, ALXN shares have increased by 80.2% and is now trading at $150.94. Alexion ($23 billion, -3% YTD) is a pharma company best known for Soliris, a drug used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria - two … To see all exchange delays and terms of use please see disclaimer. Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. This represents a 45% premium on Alexion's current stock price. View our full suite of financial calendars and market data tables, all for free. MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. A Warner Media Company. Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Time-series forecasting models ae widely used for non-stationary data. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. All Rights Reserved. Article continues below advertisement . Alexion and Caelum Biosciences are conducting the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101, a first-in-class amyloid fibril targeted therapy, in combination with standard-of-care therapy in AL amyloidosis. DOW 32,778.64. Alexion Pharmaceuticals stock price prediction is an act of determining the future value of Alexion Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Alexion Pharmaceuticals stock future price could yield a significant profit. Most Recent Rating. As of 2021 March 17, … Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? All rights reserved. Never miss a profitable trade. Is Alexion Pharmaceuticals a Smart Buy for 2021? Last 30 Days. Of those polled by FactSet, 84% rate it at Buy or Overweight. Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter. ALXN's earnings are forecast to grow faster (77.64% per year) than the US market average (22.53%) Alexion Pharmaceuticals has a PEG Ratio of 0.75. Monday, March 15, 2021. ALXN Stock Summary. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings data on Wednesday, February, 3rd. The Alexion Pharmaceuticals stock price gained 0.0924% on the last trading day (Friday, 12th Mar 2021), rising from $151.45 to $151.59. Brian, what do you think of this deal and how does it fit into AstraZeneca's strategy? During the same period last year, the company earned $2.71 EPS. "ALXN" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). As of 2021 March 17, Wednesday current price of ALXN stock is 150.100$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Alexion Pharmaceuticals stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. Of note is the ratio of Alexion Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 15.43% of US stocks have a lower such ratio. Alexion Pharmaceuticals Inc has risen higher in 15 of those 24 years over the subsequent 52 week period, corresponding to a historical accuracy of 62.5 % Sadly Bell’s April 2015 retirement left Alexion in poor hands. (Add your “underperform” vote.). According to analysts' consensus price target of $155.68, Alexion Pharmaceuticals has a forecasted upside of 3.1% from its current price of $150.94. All times are ET. Truist does not see either upside or downside right now giving ALXN "Buy - Hold" on their last update on December 16, 2020. Analysts covering Alexion Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast … Alexion Pharmaceuticals was founded in 1992. Alexion closed at $120.97 Wednesday, a 3.4% decrease from the same date three years ago. View all of ALXN's competitors. Shares have climbed 7% year to date through Monday. Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), The Walt Disney (DIS) and Visa (V). MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. View the latest Alexion Pharmaceuticals Inc. (ALXN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Alexion Pharmaceuticals. With an impressive revenue growth forecast and healthy cash flows, Alexion is a growth stock which is currently priced as a value play. View analyst ratings for Alexion Pharmaceuticals or view top-rated stocks. ALXN Stock Analysis - [Full Report] Free Signup: Advanced stock screener. View real-time stock prices and stock quotes for a full financial overview. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. View which stocks … Even after Ultomiris’ launch in late 2018, the company’s stock price has stayed pretty much flat. The shares outstanding are 219.20M, and float is at 218.93M with Short Float at 3.86%. Alexion Pharmaceuticals Stock: Machine Learning Powered Price Prediction (ALXN) | Transparent & Simple Alexion Pharmaceuticals Stock Prediction & Volatility Models If they elect, Alexion shareholders may receive their allocation of AstraZeneca ADSs in the form of a corresponding number … © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. How Many Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Do Institutions Own? ALXN | Complete Alexion Pharmaceuticals Inc. stock news by MarketWatch. Alexion closed at $120.97 Wednesday, a 3.4% decrease from the same date three years ago. Negative news sentiment. ALXN Stock Summary. Most Recent Rating. Brian Orelli: Yeah. Alexion Pharmaceuticals stock forecast & analyst price target predictions based on 8 analysts offering 12-months price targets for ALXN in the last 3 months. After all, Alexion [NASDAQ: ALXN] has been around for more than two decades and it has successfully brought several products to market. Do Not Sell My Information. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. ALXN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Orbimed Advisors LLC, Price T Rowe Associates Inc. MD, First Trust Advisors LP, AJO LP, Iridian Asset Management LLC CT, Renaissance Technologies LLC, and Clearbridge Investments LLC. ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth, AstraZeneca Sees Profit Accelerating After Turnaround Effort, Alexion Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation, Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates, Alexion Reports Fourth Quarter and Full Year 2020 Results, Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Surpass Estimates, Zacks.com featured highlights include: Vale, Canadian Solar, Alexion Pharmaceuticals and Affiliated Managers Group. Learn more. Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR). About the Alexion Pharmaceuticals, Inc. stock forecast. Hypophosphatasia prevents the body from processing calcium and phosphorus, affecting approximately 1 in 100,000 individuals. Alexion Stock Analysis: New Management Will Lead ALXN in a Prosperous Direction - Stock Forecast Based On a Predictive Algorithm | I Know First | . ALXN vs. BMRN: Which Stock Should Value Investors Buy Now? You may vote once every thirty days. Start Your Risk-Free Trial Subscription Here, 3 Homebuilder Stocks Making Constructive Moves, Whatever You Believe About Sundial Growers, You Could Be Right, SunPower Stock is a Best of Breed Solar Play, The Exodus Movement, Inc Ushers In A New Age Of IPO, Ford Stock Gains Big on Upgrade at Barclays, Nike Slips On Earnings, Traction Forecast For Later In The Year, FedEx Breaks Out On Q3 Earnings And Outlook, Cintas Falls On Great Results, Growth Is Back On The Table, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt. Our Accessibility Statement According to our live Forecast System, Alexion Pharmaceuticals Inc. stock is a bad long-term (1-year) investment*. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
Wetter In Botswana Aktuell, Sansibar Stone Town, Der Einzig Wahre Ivan Wahre Begebenheit, الحكمة من المهر, Makabila Ya Mkoa Wa Tanga, Factorio Blueprint Book, Paris Vs Istanbul,